stockportfolio.pro
CareDx, Inc. (CDNA)
Healthcare · Diagnostics & Research · NasdaqGM
CareDx, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.63M | $48.32M | $76.57M | $127.07M | $192.19M | $296.40M | $321.79M | $280.32M | $333.79M | $379.81M |
| Gross profit | $30.39M | $26.95M | $43.58M | $81.61M | — | — | $209.58M | $178.26M | $224.09M | $256.57M |
| Net income | $-39.47M | $-55.47M | $-46.76M | $-21.97M | $-18.71M | $-30.66M | $-76.61M | $-190.28M | $52.55M | $-21.35M |
| Net margin | -97.1% | -114.8% | -61.1% | -17.3% | -9.7% | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
Source: CareDx, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
What growth is priced into CDNA stock?
At today's market cap of $1.19B, CareDx, Inc. is priced for free-cash-flow growth of about 14.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $35.44M from the FY ending 2025-12-31). For comparison, revenue 14.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 14 years of CareDx, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CDNA in your portfolio →
CareDx, Inc. financial history by metric
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
CareDx, Inc. — frequently asked questions
What is CareDx, Inc.'s revenue?
CareDx, Inc. (CDNA) reported revenue of $379.81M for fiscal year 2025, up 13.8% from the prior year, according to its SEC filings.
Is CareDx, Inc. profitable?
No — CDNA reported a net loss of $-21.35M in fiscal 2025.
What is CDNA's P/E ratio?
CareDx, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is CareDx, Inc. growing?
CDNA's revenue grew at roughly 14.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does CareDx, Inc. have?
As of fiscal year 2025, CDNA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is CareDx, Inc.'s gross margin?
CDNA's gross margin was 67.6% in fiscal 2025 — gross profit of $256.57M on revenue of $379.81M.
What is CareDx, Inc.'s market cap?
CareDx, Inc. (CDNA) has a market capitalization of about $1.19B, based on the latest data in our nightly-refreshed cache.
When does CareDx, Inc.'s fiscal year end?
CDNA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CDNA stock?
At today's market cap of $1.19B, CareDx, Inc. is priced for free-cash-flow growth of about 14.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $35.44M from the FY ending 2025-12-31). For comparison, revenue 14.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from CareDx, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.